Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries.

Inotai, András; Tomek, Dominik; Niewada, Maciej; Lorenzovici, László; Kolek, Martin; Weber, Jakub; Kurrat, Anne-Katrin; Kiss, Emese Virág; Kaló, Zoltán

Inotai, András; Tomek, Dominik; Niewada, Maciej; Lorenzovici, László; Kolek, Martin; Weber, Jakub; Kurrat, Anne-Katrin; Kiss, Emese Virág; Kaló, Zoltán.

Afiliação

Inotai A; Syreon Research Institute, Budapest, Hungary.
Tomek D; Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Niewada M; Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia.
Lorenzovici L; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
Kolek M; HealthQuest Sp. zoo Sp. k., Warsaw, Poland.
Weber J; Faculty of Technical and Human Sciences, Sapientia University, Tirgu Mures, Romania.
Kurrat AK; Syreon Research Romania, Tirgu Mures, Romania.
Kiss EV; OAKS Consulting s.r.o., Prague, Czechia.
Kaló Z; OAKS Consulting s.r.o., Prague, Czechia.

Front Pharmacol ; 11: 845, 2020.

Article em En | MEDLINE | ID: mdl-32581804

Palavras-chave

Central Eastern Europe; TNF alpha inhibitor; access barriers; biologic; patient access; pharmaceutical policy; rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Ano de publicação: 2020 Tipo de documento: Article